Clinical and Preclinical Ophthalmic CRO Services | Ora

Time 2021-09-29 22:37:01

Web Name: Clinical and Preclinical Ophthalmic CRO Services | Ora

WebSite: http://www.oraclinical.com

ID:199319

Keywords:

Preclinical,and,Clinical,

Description:

Ocular Surface and Anterior Segment Ora is accelerating research for indications including dry eye, allergy, and inflammation. Learn More Posterior Segment Ora is advancing research to address vision-altering indications from inherited retinal diseases (IRDs) to other retina conditions. Learn More Ophthalmic Devices Ora supports the development of marketed products through the conduct of clinical trials, regulatory consulting, and more. Learn More Preclinical Ora’s ophthalmic experts are ready to collaborate with you at the early stages of product development, providing the milestone data you need to make important decisions. Learn More Clinical Our unique focus on ophthalmology drives our expert approach to Clinical Operations, with services across the clinical development continuum and the globe. Learn More CMC & Regulatory Ora offers CMC consulting, as well as international regulatory strategy, representation, writing, and electronic submissions. Learn More Patient and Site Solutions Our exclusive networks connect you with high-quality investigators and patients, helping you drastically accelerate recruitment. Learn More Jim McCollum, Eye Therapies “The idea is you partner with the leading experts in the world and the Ora team are experts in this area, so for us it was kind of a no brainer to sit with them and map out the plan.” Garth Cumberlidge, Mimetogen “They’ve helped us understand the different populations of dry eye and allowed us to focus on the correct populations in clinical studies. They’ve been at our side and have really been instrumental in completing a deal that we finalized with Allergan.” Won Yang, ReGenTree, LLC “One of the significant strengths of Ora is the turnkey services available, from preclinical, or CMC, or regulatory, and even statistical analysis services. We really enjoy working with them.” April, 2021 Ora Appoints David P. Bingaman, DVM, PhD, D. ACVO in Newly Created Chief Development Officer Position Read More Johnson Johnson Vision Receives Approval of World s First and Only Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itch: ACUVUE® Theravision™ with Ketotifen Read More January, 2021 White Paper: Conducting Safe and Effective Clinical Trials in the COVID-19 Environment Read More December, 2020 Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease Read More December, 2020 Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients with Dry Eye Disease Read More Increasing Your Practice’s Reach, Relevance, and Revenue with Clinical Trials Read More December, 2020 Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease Read More September, 2020 Keith Lane Presents on Ora’s Endpoints at OIS Retina Innovation Showcase Read More September, 2020 Early Ophthalmic Changes in Macula Does Not Correlate with Visual Function Read More July, 2020 Novaliq Provides Development Update on CyclASol Topical Ophthalmic Solution for the Treatment of Dry Eye Disease Read More June, 2020 Ora Receives 2020 CRO Leadership Awards for Outstanding Capabilities and Expertise Read More June, 2020 Ora, Inc. Donation to Support Ophthalmology-Focused Clinical Research Sites Impacted by COVID-19 Read More May, 2020 White Paper: Leveraging a Patient-Centric Approach to Ensure Clinical Trial Success Read More May, 2020 Oyster Point Pharma Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease Read More Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis Read More April, 2020 FDA Issues New Policy for Remote Ophthalmic Assessment and Monitoring Devices During COVID-19 Read More February, 2020 Eyestem Research announces successful completion of pre-IND meeting with FDA Read More December, 2019 iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting Read More October, 2019 Ora and SDC Congratulate Nicox on Phase II Glaucoma Trial Topline Results Read More November, 2018 Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber’s Congenital Amaurosis Type 10 Read More October, 2018 Will the Evolving Economic Landscape for Dry Eye Products Impact Investment? Read More Keith Lane Discussing Ora’s Standardized Mobility Course (Ora-VNC™) Read More June, 2018 Presbyopia Therapies Announces Primary Safety and Efficacy Endpoints met in a Phase IIb study of its Topical PRX Ophthalmic Solution for the Treatment of Presbyopia Read More March, 2018 Ora, Inc. Unifies its Clinical Environment with Veeva to Accelerate Trial Execution Read More November, 2017 TopiVert demonstrates proof of concept in Phase 1/2a study of TOP1630 in the treatment of dry eye syndrome Read More September, 2017 Making Basic Science Studies in Glaucoma More Clinically Relevant: The Need for a Consensus Read More June, 2017 Veeva Vault CTMS Gains Momentum as Industry Moves to Unify Clinical Applications and Processes Read More May, 2017 Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24% Read More April, 2017 Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production Read More March, 2017 AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications Read More January, 2017 Okogen Secures Ora to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis Read More January, 2017 Okogen Secures Ora® to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis Read More December, 2016 Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis Read More July, 2016 Allergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator Read More May, 2016 Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease Read More March, 2016 Ora Names Simon Chandler to Lead Regulatory And Clinical Operations In Europe Read More February, 2016 Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease Read More November, 2015 Ora-CAC® Model Delivers Successful Phase 3 Data for Ocular Therapeutix s DEXTENZA™ (OTX-DP) for Treatment of Allergic Conjunctivitis Read More November, 2015 Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment Read More October, 2015 Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis Read More RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259 Read More August, 2015 ARVO 2015 meeting finds connections in innovative drug delivery, therapies Read More June, 2015 Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis Read More May, 2015 Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases Read More Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model Read More April, 2015 Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome Read More April, 2015 RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. Read More March, 2015 Herantis Pharma’s Phase 2 Dry Eye study recruitment completed ahead of schedule Read More March, 2015 Biocube allergen chamber study to start for new therapeutic for rhinitis indication Read More March, 2015 Fields Medal winner Manjul Bhargava to give 2015 Commencement address, joining honorand Mark Abelson Read More March, 2015 An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye Read More February, 2015 BioLight Reports Positive Clinical Study Findings for its TeaRx™ Diagnostic Parameters for Dry Eye Syndrome Read More February, 2015 Automated Grading System for Evaluation of Superficial Punctate Keratitis Associated With Dry Eye Read More January, 2015 Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package Read More November, 2014 Ora-CAC®Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix s OTX-DP in Allergic Conjunctivitis Read More RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy Read More September, 2014 Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome Read More September, 2014 Herantis Pharma announces FDA clearance of IND for Phase 2 study of Cis-UCA Eye Drops Read More Mitotech S.A. announces the initiation of phase ii clinical trial in dry eye patients utilizing the controlled adverse environment Read More November, 2013 20 years of research and 10,000 patients: Ora dry eye system supports two largest exits in dry eye Read More November, 2013 Intellectual property within the context of establishing and protecting market share Read More October, 2013 Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome Read More July, 2013 Bausch + Lomb Acquires Option to License New Compound to Treat Dry Eye Syndrome (DES) Read More July, 2013 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye Read More June, 2013 Automated grading system for evaluation of ocular redness associated with dry eye Read More February, 2013 Aciex Enters Into Collaborative Research Agreement with Portola to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications Read More February, 2013 Investigation of extended blinks and interblink intervals in subjects with and without dry eye Read More January, 2013 Bausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular Redness Read More December, 2012 Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy Read More November, 2012 A single-center study evaluating the effect of the controlled adverse environment (CAE) model on tear film stability Read More Validation and Verification of the Allergen Biocube Model with an Intranasal Corticosteroid Read More September, 2011 First Patient Enrolled in SARcode Bioscience s Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution Read More July, 2011 Euclid Systems partners with Ora, Inc. for development of its novel collagen-based drug delivery system for glaucoma treatment Read More Accelerate your product development with Ora For over 40 years, Ora has been on the leading edge of ophthalmic product development. We have a track record for accelerating development timelines and have helped our clients garner 48 FDA approvals. Let’s work together to move your program forward. Get in touch Ora, Inc websites use cookies. By continuing to browse the site you are agreeing to our use of cookies.For more details about cookies and their use, please see our Privacy Policy.

TAGS:Preclinical and Clinical 

<<< Thank you for your visit >>>

We provide the vision and experience to help guide your Ophthalmic product from preclinical stages through commercialization. Learn more about Ora's clinical and preclinical product development services for Ophthalmology.

Hot Websites